Papillary microcarcinoma

被引:237
作者
Noguchi, Shiro [1 ]
Yamashita, Hiroto [1 ]
Uchino, Shinya [1 ]
Watanabe, Shin [1 ]
机构
[1] Noguchi Thyroid Clin & Hosp Fdn, Beppu, Oita, Japan
关键词
D O I
10.1007/s00268-007-9453-0
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background Papillary microcarcinoma (PMC) is increasing in incidence because of diagnosis by ultrasound-guided fine-needle aspiration cytology. Methods Between January 1966 and December 1995, we treated 6019 patients with papillary cancer; among them, 2070 patients with PMC were studied. Results PMC is essentially very similar to papillary cancer that is 11 mm or larger and has a very good prognosis. Smaller tumors and younger patients have a better prognosis. Among PMC, larger tumors (6-10 mm) recur in 14% at 35 years compared with 3.3% in patients with smaller tumors. Patients older than 55 years have recurrence in 40% at 30 years, with a worse prognosis than younger patients who have a recurrence rate of less than 10%. Extracapsular invasion by the primary tumor also has a higher recurrence rate. The majority of recurrences are in the neck. Therefore, annual ultrasound of the neck is effective for recurrence surveillance. Conclusions Papillary microcarcinoma is similar to larger papillary carcinomas with tumor characteristics and age-based recurrence rate that extends for many years, justifying long surveillance after surgery.
引用
收藏
页码:747 / 753
页数:7
相关论文
共 27 条
[1]
Baudin E, 1998, CANCER, V83, P553, DOI 10.1002/(SICI)1097-0142(19980801)83:3<553::AID-CNCR25>3.0.CO
[2]
2-U
[3]
INCREASED AGGRESSIVENESS OF THYROID-CANCER IN PATIENTS WITH GRAVES-DISEASE [J].
BELFIORE, A ;
GAROFALO, MR ;
GIUFFRIDA, D ;
RUNELLO, F ;
FILETTI, S ;
FIUMARA, A ;
IPPOLITO, O ;
VIGNERI, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 70 (04) :830-835
[4]
CADY B, 1985, SURGERY, V98, P1171
[5]
Papillary microcarcinoma of the thyroid - Prognostic significance of lymph node metastasis and multifocality [J].
Chow, SM ;
Law, SCK ;
Chan, JKC ;
Au, SK ;
Yau, S ;
Lau, WH .
CANCER, 2003, 98 (01) :31-40
[6]
Thyrotropin may not be the dominant growth factor in benign and malignant thyroid tumors [J].
Derwahl, M ;
Broecker, M ;
Kraiem, Z .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (03) :829-834
[7]
FUKUNAGA FH, 1975, CANCER-AM CANCER SOC, V36, P1095, DOI 10.1002/1097-0142(197509)36:3<1095::AID-CNCR2820360338>3.0.CO
[8]
2-9
[9]
Biologic basis for the treatment of microscopic, occult well-differentiated thyroid cancer [J].
Furlan, JC ;
Bedard, Y ;
Rosen, LB .
SURGERY, 2001, 130 (06) :1050-1054
[10]
GRANT S, 1984, CANCER, V54, P1625, DOI 10.1002/1097-0142(19841015)54:8<1625::AID-CNCR2820540825>3.0.CO